Compare Summit Therapeutics Inc (SMMT) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs US Bancorp — how do they compare? Summit Therapeutics Inc trades at $14.58 (market cap $10.48B), while US Bancorp trades at $63.7 (market cap $98.36B). The key difference: US Bancorp is far larger — about 9.4× Summit Therapeutics Inc's market cap, and US Bancorp pays a 3.29% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | USB | |
|---|---|---|
Market Cap | $10.48B | $98.36B |
Sector | Health | Financials |
52-Week High | $29.32 | $64.01 |
52-Week Low | $13.05 | $43.94 |
Enterprise Value | $9.90B | — |
Dividend Yield | — | 3.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
U.S. Bancorp (USB) trades at $63.71, up 0.9% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with three consecutive quarterly EPS beats, a P/E of 12.6, and a net income margin of 27.61%. Recent Q2 2026 results highlighted record revenue driven by loan growth and fee income, with the company raising its full-year revenue outlook to 7%-9% growth. Analyst consensus is a Buy with a $70.17 price target, indicating 10% upside potential.
The outlook for USB is positive, supported by earnings momentum, dividend yield near 3%, and institutional optimism. Key risks include rising debt-to-asset ratios, potential credit quality deterioration, and macroeconomic sensitivity. Investors should weigh the stock's attractive valuation against sector-wide interest rate and regulatory uncertainties for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
